Chronic Diseases and Translational Medicine, 2019 After two decades of unchanged paradigms, the treatment strategies for advanced urothelial bladder cancer have been revolutionized by emerging programmed death ligand-1 (PD-L1)/programmed death-1 (PD1) inhibition therapy.
Wei-Bo Yu, Jian-Yu Rao
doaj +3 more sources
Programmed death-1 and programmed death ligand-1 blockade for advanced urothelial carcinoma
Urological Science, 2019 Immunotherapy with immune checkpoint inhibitors (ICIs) has changed the paradigm of anticancer therapy in many cancer types, including advanced urothelial carcinoma (UC).
Jhe-Cyuan Guo +2 more
doaj +2 more sources
Indian Journal of Dermatology, 2021 Background: Extramammary Paget's disease (EMPD) is a rare skin cancer and sometimes has fatal prognosis. For progressive cases, therapeutic options are limited.
Hiroyuki Goto +2 more
doaj +3 more sources
Inhibition of Programmed Death Receptor-1/Programmed Death Ligand-1 Interactions by Ginsenoside Metabolites [PDF]
Molecules, 2020 Evidence suggests that programmed death receptor-1/programmed death ligand-1 (PD-1/PD-L1) targeted inhibitors act as an immune checkpoint blockade, indicating that these compounds may be useful in cancer immunotherapy by inhibiting the immune response ...
Nam-Hui Yim +2 more
doaj +3 more sources
Programmed Cell Death-1/Programmed Death-ligand 1 Pathway: A New Target for Sepsis
Chinese Medical Journal, 2017 Objective: Sepsis remains a leading cause of death in many Intensive Care Units worldwide. Immunosuppression has been a primary focus of sepsis research as a key pathophysiological mechanism.
Qiang Liu, Chun-Sheng Li
doaj +3 more sources
Programmed cell death-1 and programmed cell death ligand-1 antibodies-induced dysthyroidism [PDF]
Endocrine Connections, 2018 Background: Monoclonal antibodies blocking the programmed cell death-1 (PD-1) or its ligand (PD-L1) are a group of immune checkpoints inhibitors (ICIs) with proven antitumor efficacy.
Jaafar Jaafar +3 more
doaj +5 more sources
Programmed death‐ligand 1 expression in swine chronic infections and enhancement of interleukin‐2 production via programmed death‐1/programmed death‐ligand 1 blockade [PDF]
Immunity, Inflammation and Disease, 2021 Introduction Chronic infections lead to the functional exhaustion of T cells. Exhausted T cells are phenotypically differentiated by the surface expression of the immunoinhibitory receptor, such as programmed death‐1 (PD‐1).
Otgontuya Ganbaatar +13 more
doaj +4 more sources
Antagonizing programmed death-1 and programmed death ligand-1 as a therapeutic approach for gastric cancer [PDF]
Therapeutic Advances in Gastroenterology, 2016 Malignant tumor cells are equipped with mechanisms that can help them escape the surveillance by host immune system. Immune checkpoint molecules can transduce coinhibitory signals to immunocompetent cells and exert immunosuppressive roles in antitumor ...
Xiaojun Liu +3 more
doaj +3 more sources
World Journal of Gastroenterology, 2019 BACKGROUND Recently, more and more studies have demonstrated the pivotal role of programmed death 1/programmed death ligand 1 (PD-1/PD-L1) pathway in the immune evasion of tumors from the host immune system.
Min-Wei Yang +14 more
semanticscholar +3 more sources
Pneumonitis in Patients Treated With Anti-Programmed Death-1/Programmed Death Ligand 1 Therapy. [PDF]
Journal of Clinical Oncology, 2017 Purpose Pneumonitis is an uncommon but potentially fatal toxicity of anti–programmed death-1 (PD-1)/programmed death ligand 1 (PD-L1) monoclonal antibodies (mAbs). Clinical, radiologic, and pathologic features are poorly described. Methods Patients who received anti–PD-1/PD-L1 monotherapy or in combination with anti–cytotoxic T-cell lymphocyte ...
J. Naidoo +28 more
semanticscholar +3 more sources